Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mylan Confident On Advair Generic First-Round Approval

Executive Summary

President Rajiv Malik said there has been “huge movement” at the agency around executing on the first ANDA for a generic version of GlaxoSmithKline’s blockbuster Advair.

Advertisement

Related Content

Mylan's Cold-Eeze OTC Acquisition Aims To Leverage Respiratory Expertise
Advair: A Big Generic Opportunity And A Big Question Mark In 2017
Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World
Teva Advancing Two Advair Generics With Late 2017 Target
Deal Watch: Mylan Counts On A Renaissance For Expansion
Mylan Turns To Meda In Sweden For Open Door Into Consumer Market
US Patent Board To Review Mylan's Copaxone Challenge

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel